|
|||||
|
|
U.S. Food and Drug Administration approval summary: Eltrombopag for the treatment of pediatric patients with chronic immune (idiopathic) thrombocytopenia |
|
| Authors: | Lori A. Ehrlich Virginia E. Kwitkowski Gregory Reaman Chia‐Wen Ko Lei Nie Richard Pazdur Ann T. Farrell |
| Affiliation: | 1. Office of Hematology and Oncology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland;2. Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland |
| Abstract: | |
| Keywords: | eltrombopag immune thrombocytopenic purpura pediatric Promacta |